[1]陆承航,万跃.醒脑方治疗中重度脑出血的单中心随机对照临床研究[J].卒中与神经疾病杂志,2025,32(01):39-45.[doi:10.3969/j.issn.1007-0478.2025.01.007]
　Lu Chenghang*,Wan Yue..Moderate to severe intracerebral hemorrhage at acute stage treated by xingnao prescription: a monocenter, randomized, controlled study[J].Stroke and Nervous Diseases,2025,32(01):39-45.[doi:10.3969/j.issn.1007-0478.2025.01.007]
点击复制

醒脑方治疗中重度脑出血的单中心随机对照临床研究()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第32卷
期数:
2025年01期
页码:
39-45
栏目:
脑出血
出版日期:
2025-02-20

文章信息/Info

Title:
Moderate to severe intracerebral hemorrhage at acute stage treated by xingnao prescription: a monocenter, randomized, controlled study
文章编号:
1007-0478(2025)01-0039-07
作者:
陆承航; 万跃
430000 武汉,湖北中医药大学(陆承航); 湖北中医药大学、湖北省第三人民医院[万跃(通信作者)]
Author(s):
Lu Chenghang*;  Wan Yue.
*Internal Medicine-Neurology, Hubei University of Traditional Chinese Medicine, Wuhan 430000
关键词:
脑出血 醒脑方 中西医结合治疗 随机对照临床研究
Keywords:
Intracerebral hemorrhage Xingnao prescription Integrated treatment of Chinese and Western medicine Randomized controlled clinical study
分类号:
RR743.34
DOI:
10.3969/j.issn.1007-0478.2025.01.007
文献标志码:
A
摘要:
目的 探讨醒脑方治疗中重度脑出血患者的安全性及临床疗效。方法 纳入湖北省第三人民医院自2022年1月-2023年6月收治的中重度脑出血患者进行随机、双盲、对照研究设计,患者随机分成干预组和对照组,干预组患者使用醒脑方加西医常规治疗,对照组患者使用安慰剂加西医常规治疗; 采用改良Rankin量表(Modified Rankin scale,mRS)评估2组患者发病90d后的预后情况; 采用美国国立卫生研究院卒中量表(National institute of health stroke scale,NIHSS)评估2组患者治疗第7、14、28 d的神经功能缺损情况; 采用中医症候量表评估2组患者治疗第7、14 d中医症候情况; 行颅脑(Computed tomography,CT)检查,计算并记录血肿体积; 对比2组患者发病90 d后病死率; 记录患者治疗期间实验室指标水平及不良反应。结果 干预组患者治疗后第90 d的mRS 0～3分比例高于对照组(P<0.05); 干预组治疗第7、14、28 d NIHSS评分显著低于对照组(P<0.05),且干预组NIHSS评分下降趋势快于对照组(P<0.05); 干预组比对照组在治疗第14 d脑血肿体积明显减小(P<0.05),且干预组脑血肿体积下降趋势快于对照组(P<0.05); 干预组治疗第7、14 d中医症候积分明显优于对照组(P<0.05),且干预组中医症候积分下降趋势快于对照组(P<0.05); 发病90 d后病死率、不良反应及治疗期间实验室检查指标水平比较均无明显差异(P>0.05)。结论 醒脑方联合西医常规治疗可以有效改善中重度脑出血患者神经功能缺损,促进血肿吸收,改善中医症候,且该疗法具备安全性。
Abstract:
ObjectiveTo explore the safety and clinical efficacy of Xingnao prescription in treating patients with moderate and severe cerebral hemorrhage.Methods Patients with moderate to severe cerebral hemorrhage admitted to the Third People's Hospital of Hubei Province from January 2022 to June 2023 were included in a randomized, double-blind, controlled study design. The patients were randomly divided into an intervention group and a control group. Patients in the intervention group received Zhongfeng Xingnao prescription plus conventional Western medicine treatment, and patients in the control group received placebo plus conventional Western medicine treatment. The modified Rankin scale(mRS)was used to evaluate the 90th day prognosis of the two groups. The National institutes of health stroke scale(NIHSS)was used to evaluate the neurological deficits at the 7th, 14th and 28th day of treatment in the two groups. TCM syndrome scale was used to evaluate the symptoms of the two groups on the 7th and 14th day of treatment. The volume of hematoma was calculated and recorded by craniocerebral CT examination. The 90-day mortality rate was compared between the two groups, and laboratory indexes and adverse reactions were recorded during treatment.Results The mRS Score in the intervention group was significantly lower than that in the control group on the 90th day(P<0.05). NIHSS scores in the intervention group were significantly lower than those in the control group at the 7th, 14th and 28th days of treatment(P<0.05), and NIHSS in the intervention group decreased faster than that in the control group(P<0.05). The volume of cerebral hematoma in the intervention group decreased significantly compared with the control group on the 14th day of treatment(P<0.05), and the volume of cerebral hematoma in the intervention group decreased faster than that in the control group(P<0.05). The Chinese medicine syndrome score of the intervention group was significantly better than that of the control group on the 7th and 14th day of treatment(P<0.05), and the decline trend of the Chinese medicine syndrome score of the intervention group was faster than that of the control group(P<0.05). The 90th day mortality, adverse reactions and laboratory examination indexes during treatment were compared, and there was no statistical difference.Conclusion The combination of Xingnao prescription and conventional western medicine treatment can effectively improve the nerve function defect in patients with moderate and severe cerebral hemorrhage, promote the absorption of hematoma, and improve the symptoms of traditional Chinese medicine, with safe efficacy.

参考文献/References:

[1] Garg R,Biller J.Recent advances in spontaneous intracerebral hemorrhage[J].F1000Res,2019,8:F1000 Faculty Rev-F1000 Faculty 302.
[2] Magid-Bernstein J,Girard R,Polster S,et al.Cerebral hemorrhage: pathophysiology, treatment, and future directions[J].Circ Res,2022,130(8):1204-1229.
[3] Wu SM,Wu B,Liu M,et al.Stroke in China: advances and challenges in epidemiology, prevention, and management[J].Lancet Neurol,2019,18(4):394-405.
[4] Pinho J,Costa AS,Araújo JM,et al.Intracerebral hemorrhage outcome: a comprehensive update[J].J Neurol Sci,2019,398:54-66.
[5] 陈绍宏,张晓云.中风醒脑口服液治疗急性脑出血临床研究[J].中国中医急症,2004,13(12):793-794.
[6] 中华医学会神经病学分会.中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2019)[J].中华神经科杂志,2019,52(12):994-1005.
[7] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.
[8] Qureshi AI,Foster LD,Lobanova I,et al.Intensive blood pressure lowering in patients with moderate to severe grade acute cerebral hemorrhage: post Hoc analysis of antihypertensive treatment of acute cerebral hemorrhage(ATACH)-2 trial[J].Cerebrovasc Dis,2020,49(3):244-252.
[9] Lattanzi S,Brigo F,Trinka E,et al.Neutrophil-to-Lymphocyte ratio in acute cerebral hemorrhage: a system review[J].Transl Stroke Res,2019,10(2):137-145.
[10] 朱玉叶,陈昊阳,王修锁.凝血酶指标及相关临床特征与自发性脑出血患者预后的相关性分析[J].海军医学杂志,2024,45(1):26-30.
[11] 王飞.活血化瘀治疗对脑出血患者预后的影响分析[J].临床医药文献电子杂志,2019,6(5):5, 8.
[12] 于杰,吕月,李振民,等.散瘀通络汤治疗脑出血的临床研究[J].中西医结合心脑血管病杂志,2023,21(21):4006-4010.
[13] 郭世涵,罗流,卢云.中风醒脑液治疗出血性脑卒中的回顾性分析[J].中国中医急症,2023,32(6):1003-1007.
[14] 刘磊.中风醒脑颗粒治疗脑出血的临床疗效评价及抗炎机制研究[D].成都:成都中医药大学,2021.
[15] 钟磊.复元醒脑法与活血通腑法对脑出血大鼠脑保护作用的对照研究[D].泸州:西南医科大学,2023.
[16] 北京市中西医结合学会神经科专业委员会.高血压性脑出血急性期中西医结合诊疗专家共识[J].中国全科医学,2016,19(30):3641-3648.
[17] 刘娜.脑出血应用活血化瘀法治疗的临床疗效[J].内蒙古中医药,2023,42(8):14-15.
[18] 于召虎,潘源,孟令占,等.益气活血化瘀方治疗高血压性脑基底节出血术后的临床研究[J].中国中医急症,2020,29(4):633-636.
[19] 韩小芳.活血化瘀中药汤剂治疗脑出血急性期的疗效分析[J].内蒙古中医药,2023,42(6):10-11.
[20] 蓝剑,郑诚,张细江,等.醒脑静注射液联合安宫牛黄丸治疗脑出血临床研究[J].新中医,2022,54(22):56-59.

备注/Memo

备注/Memo:
基金项目:湖北省医学青年人才拔尖项目、湖北省卫健委科研项目(WJ2019F172)
更新日期/Last Update: 2025-02-20